Recently, the third-generation EGFR-TKI, osimertinib, targeting both EGFR-activating mutations as well as the gatekeeper EGFR T790M mutation, has been approved as a first-line treatment for patients with EGFR-mutant metastatic NSCLC and as a second-line therapy for patients who have developed EGFR T790M mutation after failure of the first- and/or second-generation EGFR-TKI treatment [13,14]. Here, EGFR is linked to non-small cell lung carcinoma.